Get the Stockscreener App
10.97
5.94%
0.615
After Hours:
10.96
-0.010
-0.09%
Abcellera Biologics Inc stock is traded at $10.97, with a volume of 20.05M.
It is up +5.94% in the last 24 hours and up +68.25% over the past month.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
See More
Previous Close:
$10.36
Open:
$10.32
24h Volume:
20.05M
Relative Volume:
2.47
Market Cap:
$3.36B
Revenue:
$79.21M
Net Income/Loss:
$-143.96M
P/E Ratio:
-22.87
EPS:
-0.4796
Net Cash Flow:
$-189.60M
1W Performance:
+67.99%
1M Performance:
+68.25%
6M Performance:
+253.87%
1Y Performance:
+139.52%
1-Day Range:
$10.22
$11.06
1-Week Range:
$6.35
$11.06
52-Week Range:
$2.745
$11.06
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
10.97 | 3.17B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Director Michael R. Hayden Donates 50,000 Shares to Charity via Genworks 2 Consulting - Kalkine Media
AbCellera Biologics Announces Oversubscribed $200 Million Offering - TipRanks
AbCellera Enters Underwriting Agreement for $187M Equity Offering With Jefferies, J.P. Morgan - TradingView
AbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - AOL.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Abcellera Biologics Inc Nasdaq ABCL Canada F-35 Fighter Jet Purchase (hA9yM7fsuE) - Mshale
ABCL Looks 82.6% Overvalued on GF Value™ - GuruFocus
AbCellera prices $200 million public offering at $9.75/share - Investing.com
AbCellera prices $200 million public offering at $9.75/share By Investing.com - Investing.com Nigeria
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - lincolnjournal.com
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - AOL.com
AbCellera Biologics stock analysis: momentum vs. fundamentals By Investing.com - Investing.com Canada
AbCellera Biologics stock analysis: momentum vs. fundamentals - Investing.com
What's Going on With AbCellera Biologics Stock On Wednesday? - Benzinga
AbCellera Biologics (NASDAQ:ABCL) Shares Gap DownHere's Why - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL) - Moomoo
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stoc - Benzinga
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera offers up USD 200m in stock to support NK3 menopause antibody - AllSci
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Ifc (po852VQ6WV) - Mshale
AbCellera’s ABCL635 Meets Primary Endpoints in Phase 2 for Menopause Symptoms - The Clinical Trial Vanguard
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Yahoo Finance
AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story - simplywall.st
AbCellera Biologics | 424B5: Prospectus - Moomoo
AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031 - Bybit
Truist raises AbCellera stock price target on trial results By Investing.com - Investing.com South Africa
AbCellera launches $200-million equity offering on heels of strong menopause trial results - The Globe and Mail
AbCellera launches $200 million public offering of common shares By Investing.com - Investing.com UK
ABCL Looks 72.1% Overvalued on GF Value™ - GuruFocus
Why is Abcellera Biologics stock sliding today? - Investing.com
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results - finance.yahoo.com
AbCellera stock falls on $200M public offering launch By Investing.com - Investing.com India
AbCellera stock falls on $200M public offering launch - Investing.com
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading - Seeking Alpha
AbCellera launches $200 million public offering of common shares - Investing.com
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
ABCL Maintained by Truist Securities -- Price Target Raised to $30 - GuruFocus
AbCellera Shares Jump on Trial Results Amid Interest in Menopause Drugs - Moomoo
Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7%Here's What Happened - MarketBeat
Truist raises AbCellera stock price target on trial results - Investing.com
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News. -- Barrons.com - moomoo.com
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data - Yahoo! Finance Canada
AbCellera stock surges on ABCL635 menopause Phase 2 trial results - qz.com
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes - BioSpace
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run? - finance.yahoo.com
AbCellera Soars Nearly 40% as Menopause Drug Data ‘Wows’ Analysts - NAI500
ABCL635, a drug for hot flash treatment, shows positive results in mid-stage trials; AbCellera Biologics (ABCL.US) surges in response - Bitget
Positive results from the mid-stage trial of the hot flash treatment drug ABCL635, AbCellera Biologics (ABCL.US) surges in response - Bitget
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):